[go: up one dir, main page]

MX2010003269A - Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. - Google Patents

Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.

Info

Publication number
MX2010003269A
MX2010003269A MX2010003269A MX2010003269A MX2010003269A MX 2010003269 A MX2010003269 A MX 2010003269A MX 2010003269 A MX2010003269 A MX 2010003269A MX 2010003269 A MX2010003269 A MX 2010003269A MX 2010003269 A MX2010003269 A MX 2010003269A
Authority
MX
Mexico
Prior art keywords
inhibition
treating cancer
aurora kinase
derivatives useful
pyrrolotriazine derivatives
Prior art date
Application number
MX2010003269A
Other languages
English (en)
Inventor
Steven Magnuson
Philip Wickens
Zhonghua Zhang
Ning Qi
Xin Ma
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40511812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2010003269A publication Critical patent/MX2010003269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se relaciona a compuestos novedosos y procesos para su preparación, métodos para tratar enfermedades, particularmente Cáncer, que comprenden administrar los compuestos, y métodos para hacer composiciones farmacéuticas para el tratamiento o prevención de desordenes, particularmente Cáncer.
MX2010003269A 2007-09-25 2008-09-22 Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. MX2010003269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99514707P 2007-09-25 2007-09-25
PCT/US2008/077211 WO2009042543A1 (en) 2007-09-25 2008-09-22 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase

Publications (1)

Publication Number Publication Date
MX2010003269A true MX2010003269A (es) 2010-08-02

Family

ID=40511812

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003269A MX2010003269A (es) 2007-09-25 2008-09-22 Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.

Country Status (12)

Country Link
US (1) US8138336B2 (es)
EP (1) EP2203060A4 (es)
JP (2) JP5678661B2 (es)
KR (1) KR20100075932A (es)
CN (1) CN101820762B (es)
AU (1) AU2008304620A1 (es)
CA (1) CA2700489A1 (es)
IL (1) IL204692A0 (es)
MX (1) MX2010003269A (es)
TW (1) TW200930719A (es)
WO (1) WO2009042543A1 (es)
ZA (1) ZA201002438B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AU2006320440B2 (en) * 2005-12-02 2012-04-05 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009042543A1 (en) * 2007-09-25 2009-04-02 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
JP5592890B2 (ja) * 2008-10-08 2014-09-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
US8586598B2 (en) * 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
CN103929961A (zh) * 2011-06-20 2014-07-16 美国阿尔茨海默病研究所公司 化合物及其治疗应用
CA2862981C (en) 2011-12-15 2020-02-25 Bayer Pharma Aktiengesellschaft Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
ES2581065T3 (es) 2012-02-23 2016-08-31 Bayer Intellectual Property Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
SMT202300480T1 (it) 2016-03-28 2024-01-10 Incyte Corp Composti di pirrolotriazina come inibitori di tam
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DK1183033T3 (da) * 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007064932A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc. Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
AU2006320440B2 (en) * 2005-12-02 2012-04-05 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009042543A1 (en) * 2007-09-25 2009-04-02 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase

Also Published As

Publication number Publication date
JP5678661B2 (ja) 2015-03-04
IL204692A0 (es) 2010-11-30
EP2203060A4 (en) 2010-12-22
HK1144392A1 (en) 2011-02-18
AU2008304620A1 (en) 2009-04-02
CN101820762A (zh) 2010-09-01
JP5797799B2 (ja) 2015-10-21
CN101820762B (zh) 2014-07-30
JP2014129418A (ja) 2014-07-10
KR20100075932A (ko) 2010-07-05
US20100273800A1 (en) 2010-10-28
TW200930719A (en) 2009-07-16
ZA201002438B (en) 2010-12-29
US8138336B2 (en) 2012-03-20
WO2009042543A1 (en) 2009-04-02
EP2203060A1 (en) 2010-07-07
JP2010540455A (ja) 2010-12-24
CA2700489A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200714604A (en) Substituted heterocycles and the uses thereof
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2006034154A3 (en) Salts of 5-azacytidine
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200628473A (en) Novel heterocycles
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
MY177206A (en) Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith
TW200740808A (en) Inhibiteurs de proteines kinases
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
PL1732926T3 (pl) Inhibitory kinezyn motorycznych